Agilent: FDA Approves TRS100 Method For Content Uniformity Testing By Teva
(RTTNews) - Agilent Technologies Inc. (A) said the FDA has approved a content uniformity method using the Agilent TRS100 Raman quantitative pharmaceutical analysis system. The submitting company, Teva Pharmaceutical Industries, is an Agilent Raman spectroscopy customer. Agilent noted that the approval of this CU method using the TRS100 is specific to Teva.
Geoff Winkett, vice president of Agilent's Molecular Spectroscopy division, said: "Teva joins other customers who have adopted this technology for CU testing for all the benefits it brings. It is a substantial investment to change manufacturing and QC processes, and an FDA approval minimizes the perceived risk of adopting this new technology."
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.